Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

[1]  A. Bringmann,et al.  Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone , 2009, Cellular and Molecular Life Sciences.

[2]  H. Rammensee,et al.  Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA , 2008, Journal of immunotherapy.

[3]  E. Gilboa,et al.  Robust CD4+ and CD8+ T cell responses to SIV using mRNA‐transfected DC expressing autologous viral Ag , 2007, European journal of immunology.

[4]  H. Rammensee,et al.  Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent , 2007, Gene Therapy.

[5]  L. Kanz,et al.  BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. , 2006, Cancer research.

[6]  E. Gilboa,et al.  Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. , 2007, Cancer research.

[7]  G. Bartsch,et al.  Antigen-independent immune responses after dendritic cell vaccination , 2007, Cancer Immunology, Immunotherapy.

[8]  A. Palucka,et al.  Dendritic cell-based vaccination against cancer. , 2006, Hematology/oncology clinics of North America.

[9]  Peter Brossart,et al.  Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. , 2006, Cancer research.

[10]  T. Holderried,et al.  Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  L. Kanz,et al.  Intradermal RNA-Vaccination of Patients with Metastatic Renal Cell Carcinoma. , 2005 .

[12]  P. Brossart,et al.  Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes , 2005, Cancer Gene Therapy.

[13]  H. Rammensee,et al.  Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. , 2005, Genetic vaccines and therapy.

[14]  G. Schuler,et al.  Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation , 2005, The Journal of Immunology.

[15]  A. Heine,et al.  Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. , 2005, Blood.

[16]  P. Brossart,et al.  Dendritic cell-based cancer immunotherapy targeting MUC-1 , 2005, Cancer Immunology, Immunotherapy.

[17]  G. Bartsch,et al.  Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide , 2005, Cancer Immunology, Immunotherapy.

[18]  H. Rammensee,et al.  Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines , 2004, Cellular and Molecular Life Sciences CMLS.

[19]  S. Pascolo.  Messenger RNA-based vaccines , 2004, Expert opinion on biological therapy.

[20]  M. Atkins,et al.  Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.

[21]  P. Brossart,et al.  Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. , 2004, Blood.

[22]  H. Rammensee,et al.  Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis , 2004, Cancer Research.

[23]  L. Kanz,et al.  Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.

[24]  G. Schuler,et al.  Antigen loading of dendritic cells with whole tumor cell preparations. , 2003, Journal of immunological methods.

[25]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[26]  H. Pandha,et al.  Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. , 2003, The Lancet. Oncology.

[27]  P. Albers,et al.  Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. , 2003, Human gene therapy.

[28]  A. Ballestrero,et al.  Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer , 2003, Cancer Gene Therapy.

[29]  P. Brossart,et al.  Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes , 2003, Gene Therapy.

[30]  P. Brossart,et al.  Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. , 2003, Blood.

[31]  G. Bartsch,et al.  Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[33]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[34]  H. Rammensee,et al.  In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, European journal of immunology.

[35]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[37]  H. Klocker,et al.  Human renal‐cell carcinoma tissue contains dendritic cells , 1996, International journal of cancer.

[38]  D. Curiel,et al.  Characterization of a messenger RNA polynucleotide vaccine vector. , 1995, Cancer research.

[39]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[40]  A. Belldegrun,et al.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.

[41]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.